Related Experiment Video
Updated: Jun 6, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
Published on: May 25, 2020
Profile of the glaucomas and intervention in a large eye care centre in south-east Nepal
Introduction:
Glaucoma is the second leading cause of blindness worldwide.
Objective:
To estimate the prevalence and risk factors of glaucoma and modes of therapeutical intervention in a rural population of a developing country.
Patients And Methods:
A single centre-based cross-sectional study was carried out over a seven-month period in Sagarmatha Choudhary Eye Hospital (SCEH), Lahan/NEPAL, including the patients with glaucoma.
Outcome Measurement:
The patients' demography, type of the glaucomas, visual acuity, vertical cup-disc ratio, intra-ocular pressure and visual field findings were the parameters studied.
Results:
A total of 3986 eyes with suspected glaucoma were identified. 53.7% of the patients were between 41-60 years of age. 53.9% were male. 26.5% were blind or severely visually impaired. 37.2% had IOP more than 35 mmHg. 46.4% had vertical cup-disc ratio (VCDR) higher than 0.8. Severe visual field defects were found in 28.4% eyes. 35.3% eyes had primary angle-closure glaucoma, 22.6% eyes primary open-angle glaucoma, and 14.6% eyes normaltension glaucoma. 10.2% eyes suffered from lens induced glaucoma. Only in 9 eyes was pseudoexfoliation syndrome with glaucoma diagnosed. 25.7% eyes were advised for trabeculectomy. 11.5% eyes underwent extra-capsular cataract surgery. IOP lowering medication was prescribed in 5.9% patients.
Conclusions:
The most common glaucoma seen in the out-patient department of a large eyecare centre in South-East Nepal is primary angle-closure glaucoma. 25% of the glaucoma patients are visually impaired or blind at the time of presentation. In more than one-fourth of the patients, trabeculectomy is the therapy of choice.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment